Quantum BioPharma’s Lucid-MS Program Featured in BioMedWire Editorial as Promising MS Treatment

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (MS), a disease affecting more than 2.9 million people worldwide. The article highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS, and notes that the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease.

Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, leading to the progressive loss of neurological function. Current treatments for MS primarily focus on managing symptoms or reducing relapse rates, but few address the root cause of myelin damage. Quantum BioPharma’s approach could represent a paradigm shift if successfully developed.

The company is a biopharmaceutical firm dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The editorial in BioMedWire underscores the potential of this candidate and the importance of advancing it into human trials.

Quantum BioPharma also invented UNBUZZD, a product aimed at alcohol misuse, and spun out its OTC version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), retaining a 19.84% stake as of March 31, 2026, and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. However, the core focus remains on Lucid-MS as the lead compound.

According to the press release, the full editorial can be accessed at https://ibn.fm/KdvrI. For the latest news and updates regarding QNTM, investors can visit the company’s newsroom at https://ibn.fm/QNTM.

The inclusion in the BioMedWire editorial highlights the growing interest in Quantum BioPharma’s approach to MS. With Phase 2 trials on the horizon, the company is poised to generate clinical data that could validate its novel mechanism. If successful, Lucid-MS could offer a new therapeutic option for millions of MS patients who currently have limited choices for disease modification. The editorial serves as a platform to raise awareness among investors and the medical community about the potential of this first-in-class therapy.